Because its trial designs do not meet even the basic minimum criteria set forth by the Food and Drug Administration (FDA) for new vaccines, AstraZeneca’s adenovirus-vector vaccine for the Wuhan coronavirus (COVID-19) will “never be licensed in the U.S.,” says SVB Leerink health-care analyst George Porges.
Despite claims that the jab is 70 percent effective – or 90 percent effective, depending on which skewed dataset you look at – AstraZeneca’s COVID-19 injection, known formally as ChAdOx1, is neither safe nor effective.
The drug giant “tried to embellish” its early reporting on the jab by claiming 90 percent efficacy in a limited subset of subjects who received a “modified” dose. These individuals had not yet received the “full dose,” which came four weeks later and produced less-stellar results.
In Porges’ view, ChAdOx1 will never be licensed in the United States for a number of reasons, perhaps the most significant being that the basic FDA thresholds for scientific proof of safety and efficacy have not been, and never will be, met.
Not only that, but AstraZeneca’s COVID-19 vaccine is harming trial participants by giving them serious neurological conditions that are far worse than anything the novel virus itself could produce.
Porges’ own thesis that “all spike protein vaccines are created equal” has been confounded by the findings of these halted trials, which also calls into question other adenovirus-vector vaccines being produced by Big Pharma competitors such as Johnson & Johnson (J&J).
On the flip side, Porges is focusing his sights on adjuvanted protein sub unit vaccines such as those being develop by Novavax and GlaxoSmithKline (GSK). These engineered synthetic virus vaccines, he says, could be more effective at “boosting” immunity to COVID-19.
“… but it appears that the occurrence of pre-existing or post-vaccination immunity to the vector has a significant dampening effect on the efficacy of the vaccines (and may confer risk as well) and for this reason we believe these products are likely to be regarded as relatively marginal suppliers in the COVID vaccine market of the future,” he adds.
AstraZeneca’s ongoing clinical trial is still claiming 70 percent vaccine efficacy following 132 infection events. Meanwhile, the media is admitting that the results are “a little bit more mixed” than those put out by the likes of Pfizer and Moderna, and are also more “confusing.”
This is saying a lot, seeing as how Pfizer and Moderna’s “amazing” results are completely bogus and backed by nothing more than empty promises.
Big Pharma, the mainstream media, and other key players in the COVID-19 vaccine game continue to pretend as though they are perplexed about mass public resistance to all of these vaccines, no matter their respective technologies.
At least half of the American public says it will not be getting jabbed with any COVID-19 vaccine because they are being rushed onto the market at “warp speed” while their manufacturers hold zero liability for any adverse events that may result.
“I don’t understand this concern people have that a multi-billion dollar global corporation would rush a product to market in order to sell it for untold billions in profits despite potentially harmful side effects, knowing they cannot be sued due to the law protecting vaccine manufacturers,” wrote one Zero Hedge commenter sarcastically.
“Some people are just tin foil hat conspiracy theorists, I guess.”
Another echoed that sentiment, noting that Moderna itself admitted back in 2017 that mRNA vaccines, which is the type it is currently developing for COVID-19, “will never be safe enough for use in humans.”
To keep up with the latest news about the COVID-19, be sure to check out Pandemic.news.
Sources for this article include: